Maze Therapeutics Inc
MAZE14.416USD
-0.484-3.25%
交易中 （美东）报价延迟15分钟
631.39M总市值
亏损市盈率 TTM
关于 Maze Therapeutics Inc 公司
Maze Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司致力于利用其 Maze Compass 平台，利用人类遗传学和变异功能化的力量，开发用于治疗肾脏、心血管和相关代谢疾病（包括肥胖症）的小分子精准药物。Compass 平台旨在通过临床试验设计为药物发现和开发过程的所有阶段提供信息，推进两个全资拥有的领先项目 MZE829 和 MZE782，每个项目都代表了一种基于精准医学的新型慢性肾病 (CKD) 方法。其领先项目 MZE829 是一种口服小分子载脂蛋白 L1 (APOL1) 抑制剂，用于治疗患有 APOL1 肾病 (AKD) 的患者。其第二个领先项目 MZE782 是一种口服小分子溶质转运蛋白 SLC6A19 抑制剂，这是一种新型 CKD 靶点。
公司简介
公司代码MAZE
公司名称Maze Therapeutics Inc
上市日期Jan 31, 2025
CEODr. Jason V. Coloma, Ph.D.
员工数量125
证券类型Ordinary Share
年结日Jan 31
公司地址171 Oyster Point Boulevard, Suite 300
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94080
电话16508505070
网址https://www.mazetx.com/
公司代码MAZE
上市日期Jan 31, 2025
CEODr. Jason V. Coloma, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
167.50M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Third Rock Ventures, LLC
16.04%
Frazier Life Sciences Management, L.P.
10.16%
ARCH Venture Partners
9.41%
Deep Track Capital LP
7.46%
Matrix Capital Management Company, LP
5.68%
Other
51.25%
持股股东
持股股东
占比
Third Rock Ventures, LLC
16.04%
Frazier Life Sciences Management, L.P.
10.16%
ARCH Venture Partners
9.41%
Deep Track Capital LP
7.46%
Matrix Capital Management Company, LP
5.68%
Other
51.25%
股东类型
持股股东
占比
Venture Capital
39.35%
Private Equity
15.77%
Hedge Fund
15.41%
Investment Advisor/Hedge Fund
13.46%
Individual Investor
5.91%
Investment Advisor
5.58%
Endowment Fund
1.46%
Family Office
1.10%
Research Firm
0.11%
Other
1.87%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
99
42.51M
97.06%
+14.68M
2025Q1
93
44.69M
102.04%
+15.27M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Third Rock Ventures, LLC
7.02M
16.04%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.45M
10.16%
+322.34K
+7.81%
Apr 25, 2025
ARCH Venture Partners
4.12M
9.41%
--
--
Mar 31, 2025
Deep Track Capital LP
3.27M
7.46%
+245.64K
+8.12%
Mar 31, 2025
Matrix Capital Management Company, LP
2.49M
5.68%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
2.46M
5.61%
+2.00
+0.00%
Mar 31, 2025
Alphabet, Inc.
2.41M
5.51%
--
--
Mar 31, 2025
Andreessen Horowitz
1.70M
3.89%
+1.70M
--
Mar 31, 2025
Janus Henderson Investors
1.25M
2.85%
+1.25M
--
Mar 31, 2025
General Catalyst Partners
1.04M
2.37%
+1.04M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
ALPS Medical Breakthroughs ETF
0.36%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.82%
ALPS Medical Breakthroughs ETF
占比0.36%
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.01%
iShares Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
Schwab U.S. Small-Cap ETF
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
